PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Abstract PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinic...

Full description

Bibliographic Details
Main Authors: Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, Simon T. Barry
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:http://link.springer.com/article/10.1186/s40425-018-0457-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0457-0

Similar Items